Jim Simons Mereo Biopharma Group PLC Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,480,471 shares of MREO stock, worth $3.01 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,480,471

Previous 1,350,471 9.63%

Holding current value

$3.01 Million

Previous $3.04 Million 32.06%

% of portfolio

0.01%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$1.76 - $2.87 $228,800 - $373,100	130,000 Added 9.63%	1,480,471 $4.01 Million
Q1 2025 May 14, 2025	BUY	$2.25 - $3.76 $362,250 - $605,360	161,000 Added 13.54%	1,350,471 $3.04 Million
Q4 2024 Feb 13, 2025	SELL	$3.29 - $4.62 $381,311 - $535,458	-115,900 Reduced 8.88%	1,189,471 $4.16 Million
Q3 2024 Nov 13, 2024	SELL	$3.45 - $4.87 $1.58 Million - $2.22 Million	-456,632 Reduced 25.92%	1,305,371 $5.37 Million
Q2 2024 Aug 09, 2024	BUY	$2.58 - $4.25 $231,410 - $381,199	89,694 Added 5.36%	1,762,003 $6.34 Million
Q1 2024 May 13, 2024	SELL	$2.3 - $4.05 $289,110 - $509,085	-125,700 Reduced 6.99%	1,672,309 $5.52 Million
Q4 2023 Feb 13, 2024	BUY	$1.19 - $2.42 $83,822 - $170,462	70,439 Added 4.08%	1,798,009 $4.15 Million
Q3 2023 Nov 14, 2023	SELL	$1.15 - $1.67 $58,882 - $85,507	-51,202 Reduced 2.88%	1,727,570 $2.23 Million
Q2 2023 Aug 11, 2023	BUY	$0.79 - $1.43 $681,661 - $1.23 Million	862,863 Added 94.21%	1,778,772 $2.35 Million
Q1 2023 May 12, 2023	SELL	$0.71 - $1.22 $242,436 - $416,581	-341,460 Reduced 27.16%	915,909 $647,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $1.01 $11,877 - $23,992	23,755 Added 1.93%	1,257,369 $943,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.73 $512,258 - $1.08 Million	624,705 Added 102.59%	1,233,614 $1.06 Million
Q2 2022 Aug 12, 2022	BUY	$0.33 - $1.69 $107,285 - $549,434	325,109 Added 114.56%	608,909 $682,000
Q1 2022 May 13, 2022	BUY	$1.04 - $1.7 $65,728 - $107,440	63,200 Added 28.65%	283,800 $318,000
Q4 2021 Feb 11, 2022	SELL	$1.51 - $2.59 $269,233 - $461,797	-178,300 Reduced 44.7%	220,600 $353,000
Q3 2021 Nov 12, 2021	BUY	$2.2 - $3.17 $250,360 - $360,746	113,800 Added 39.92%	398,900 $965,000
Q2 2021 Aug 13, 2021	BUY	$2.94 - $4.08 $52,626 - $73,032	17,900 Added 6.7%	285,100 $904,000
Q1 2021 May 13, 2021	SELL	$2.6 - $4.43 $239,200 - $407,560	-92,000 Reduced 25.61%	267,200 $900,000
Q4 2020 Feb 10, 2021	BUY	$1.95 - $3.6 $659,100 - $1.22 Million	338,000 Added 1594.34%	359,200 $1.29 Million
Q3 2020 Nov 13, 2020	SELL	$2.55 - $3.29 $74,460 - $96,068	-29,200 Reduced 57.94%	21,200 $56,000
Q2 2020 Aug 13, 2020	BUY	$1.0 - $3.4 $50,400 - $171,360	50,400 New	50,400 $154,000
Q1 2020 May 14, 2020	SELL	$0.8 - $3.21 $101,058 - $405,496	-126,323 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$1.1 - $3.7 $43,780 - $147,260	-39,800 Reduced 23.96%	126,323 $414,000
Q3 2019 Nov 13, 2019	SELL	$2.22 - $4.14 $66,156 - $123,371	-29,800 Reduced 15.21%	166,123 $495,000
Q2 2019 Aug 12, 2019	BUY	$2.52 - $6.5 $493,725 - $1.27 Million	195,923 New	195,923 $494,000

Others Institutions Holding MREO

# of Institutions

Shares Held

98.2M

Call Options Held

2.28M

Put Options Held

761K

View Full List

About Mereo Biopharma Group plc

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $254M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

More about MREO

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account